Thrombotic Microangiopathy in Transplantation and Malignancy

ABSTRACT

Thrombotic microangiopathy (TMA) after hematopoietic stem-cell transplantation (HSCT) or solid-organ transplantation is a serious complication that may be associated with diverse clinical conditions. The reported incidence varies widely, in part due to different diagnostic criteria. Currently, the diagnosis is based mostly on clinical features and is often uncertain; many disease or therapy-related complications in transplantation and malignancy can manifest clinical features of TMA. Risk factors for TMA post HSCT include the type of conditioning regimen, the presence graft-versus-host disease (GVHD), the use of calcineurin inhibitors (cyclosporine and tacrolimus) for GVHD prophylaxis, and infection. Cyclosporin and tacrolimus are the most commonly reported agents associated with TMA in solid-organ (mainly kidney) transplantations. Cancer-related TMA may be associated with chemotherapy or the malignancy itself. Compared with idiopathic TMA (thrombotic thrombocytopenic purpura), the outcome for patients with TMA post-HSCT or disseminated malignancy is poor. The efficacy of plasma exchange in the treatment of TMA post-HSCT or malignancy is uncertain. In the future, objective criteria integrating laboratory features (including tissue pathology, quantitative hematology, and endothelial cell functionality) with clinical features may assist in the diagnostic accuracy of TMA post HSCT, which would allow better evaluation of treatment modalities and better prediction of prognosis and outcomes.

KEYWORDS

Thrombotic microangiopathy - thrombotic thrombocytopenic purpura (TTP) - hemolytic uremic syndrome (HUS) - hematopoietic stem cell - cancer - drugs

REFERENCES

• 1 George J N, Li X, McMinn J R et al.. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.  Transfusion. 2004;  44 294-304
• 2 Holler E, Kolb H J, Moller A et al.. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.  Blood. 1990;  75 1011-1016
• 3 Zeigler Z R, Shadduck R K, Nemunaitis J, Andrews D F, Rosenfeld C S. Bone marrow transplant-associated thrombotic microangiopathy: a case series.  Bone Marrow Transplant. 1995;  15 247-253
• 4 Kanamori H, Takaishi Y, Takabayashi M et al.. Clinical significance of fragmented red cells after allogeneic bone marrow transplantation.  Int J Hematol. 2003;  77 180-184
• 5 Pettitt A R, Clark R E. Thrombotic microangiopathy following bone marrow transplantation.  Bone Marrow Transplant. 1994;  14 495-504
• 6 Nishida T, Hamaguchi M, Hirabayashi N et al.. Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease.  Bone Marrow Transplant. 2004;  33 1143-1150
• 7 Shidham V B, Chang C C, Shidham G et al.. Colon biopsies for evaluation of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients.  BMC Gastroenterol. 2003;  3 5
• 8 Roy V, Rizvi M A, Vesely S K, George J N. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes.  Bone Marrow Transplant. 2001;  27 641-646
• 9 Paquette R L, Tran L, Landaw E M. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis.  Bone Marrow Transplant. 1998;  22 351-357
• 10 Iacopino P, Pucci G, Arcese W et al.. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO).  Bone Marrow Transplant. 1999;  24 47-51
• 11 Fuge R, Bird J M, Fraser A et al.. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation.  Br J Haematol. 2001;  113 58-64
• 12 Sarode R, McFarland J G, Flomenberg N et al.. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation.  Bone Marrow Transplant. 1995;  16 271-275
• 13 Ruutu T, Hermans J, Niederwieser D et al.. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).  Br J Haematol. 2002;  118 1112-1119
• 14 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.  Mayo Clin Proc. 2003;  78 421-430
• 15 Daly A S, Hasegawa W S, Lipton J H, Messner H A, Kiss T L. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver.  Transfus Apheresis Sci. 2002;  27 3-12
• 16 Hahn T, Alam A R, Lawrence D et al.. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion.  Transplantation. 2004;  78 1515-1522
• 17 Shimoni A, Yeshurun M, Hardan I et al.. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.  Biol Blood Marrow Transplant. 2004;  10 484-493
• 18 Uderzo C, Fumagalli M, De Lorenzo P et al.. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation.  Bone Marrow Transplant. 2000;  26 1005-1009
• 19 Schriber J R, Herzig G P. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Semin Hematol. 1997;  34 126-133
• 20 Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Hemolytic uremic syndrome after allogeneic or autologous hematopoietic stem cell transplantation for childhood malignancies.  Bone Marrow Transplant. 1998;  21 281-286
• 21 Waiser J, Budde K, Rudolph B, Ortner M A, Neumayer H H. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection.  Am J Kidney Dis. 1999;  34 556-559
• 22 Matsuda Y, Hara J, Miyoshi H et al.. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children.  Bone Marrow Transplant. 1999;  24 919-923
• 23 Fassas A B, Buddharaju L N, Rapoport A et al.. Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation.  Leuk Lymphoma. 2001;  42 801-804
• 24 Takatsuka H, Wakae T, Toda A et al.. Association of Helicobacter pylori with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome after bone marrow transplantation.  Clin Transplant. 2004;  18 547-551
• 25 Plews D E, Turner M L, Wallace W H. Plasma exchange as successful treatment of thrombotic thrombocytopenic purpura post autologous bone marrow transplant in a child.  Bone Marrow Transplant. 2000;  25 679-680
• 26 Furlan M, Robles R, Solenthaler M et al.. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 27 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 28 van der Plas R M, Schiphorst M E, Huizinga E G et al.. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura.  Blood. 1999;  93 3798-3802
• 29 Allford S L, Bird J M, Marks D I. Thrombotic thrombocytopenic purpura following stem cell transplantation.  Leuk Lymphoma. 2002;  43 1921-1926
• 30 Arai S, Allan C, Streiff M et al.. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.  Hematol J. 2001;  2 292-299
• 31 Vesely S K, George J N, Lammle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 32 Daly A S, Xenocostas A, Lipton J H. Transplantation-associated thrombotic microangiopathy: twenty-two years later.  Bone Marrow Transplant. 2002;  30 709-715
• 33 Dlott J S, Danielson C F, Blue-Hnidy D E, McCarthy L J. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review.  Ther Apher Dial. 2004;  8 102-111
• 34 Diamant M, Tushuizen M E, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease?.  Eur J Clin Invest. 2004;  34 392-401
• 35 Jimenez J J, Jy W, Mauro L M, Horstman L L, Ahn Y S. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease.  Br J Haematol. 2001;  112 81-90
• 36 Jy W, Jimenez J J, Mauro L M et al.. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation.  J Thromb Haemost. 2005;  3 1301-1308
• 37 Takatsuka H, Wakae T, Mori A et al.. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation.  Bone Marrow Transplant. 2002;  29 907-911
• 38 Bernardo A, Ball C, Nolasco L, Moake J F, Dong J F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow.  Blood. 2004;  104 100-106
• 39 Nabhan C, Kwaan H C. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura.  Hematol Oncol Clin North Am. 2003;  17 177-199
• 40 Chopra R, Eaton J D, Grassi A et al.. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.  Br J Haematol. 2000;  111 1122-1129
• 41 Corti P, Uderzo C, Tagliabue A et al.. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation.  Bone Marrow Transplant. 2002;  29 542-543
• 42 Rock G A, Shumak K H, Buskard N A et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.  N Engl J Med. 1991;  325 393-397
• 43 Rock G A. Management of thrombotic thrombocytopenic purpura.  Br J Haematol. 2000;  109 496-507
• 44 Teruya J, Styler M, Verde S, Topolsky D, Crilley P. Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation.  J Clin Apheresis. 2001;  16 169-174
• 45 Milone J, Napal J, Bordone J, Etchegoyen O, Morales V. Complete response in severe thrombotic microangiopathy post bone marrow transplantation (BMT-TM) after multiple plasmaphereses.  Bone Marrow Transplant. 1998;  22 1019-1021
• 46 Kolker O, Sviri S, Linton D M et al.. Plasmapheresis for thrombotic thrombocytopenic purpura following bone marrow transplantation.  Acta Haematol. 2001;  105 156-158
• 47 Zeigler Z R, Shadduck R K, Nath R, Andrews III D F. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy.  Bone Marrow Transplant. 1996;  17 81-86
• 48 Dua A, Zeigler Z R, Shadduck R K et al.. Apheresis in grade 4 bone marrow transplant associated thrombotic microangiopathy: a case series.  J Clin Apheresis. 1996;  11 176-184
• 49 Silva V A, Frei-Lahr D, Brown R A, Herzig G P. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation.  J Clin Apheresis. 1991;  6 16-20
• 50 Muller S, Schutt P, Bojko P et al.. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.  Ann Hematol. 2005;  84 110-114
• 51 Al-Zahrani H, Gupta V, Minden M D, Messner H A, Lipton J H. Vascular events associated with alpha interferon therapy.  Leuk Lymphoma. 2003;  44 471-475
• 52 Zuber J, Martinez F, Droz D, Oksenhendler E, Legendre C. Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature.  Medicine (Baltimore). 2002;  81 321-331
• 53 Singh N, Gayowski T, Marino I R. Hemolytic uremic syndrome in solid-organ transplant recipients.  Transpl Int. 1996;  9 68-75
• 54 Reynolds J C, Agodoa L Y, Yuan C M, Abbott K C. Thrombotic microangiopathy after renal transplantation in the United States.  Am J Kidney Dis. 2003;  42 1058-1068
• 55 Chiurchiu C, Ruggenenti P, Remuzzi G. Thrombotic microangiopathy in renal transplantation.  Ann Transplant. 2002;  7 28-33
• 56 Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.  Pediatr Nephrol. 2003;  18 1095-1101
• 57 Ducloux D, Rebibou J M, Semhoun-Ducloux S et al.. Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis.  Transplantation. 1998;  65 1405-1407
• 58 Lahlou A, Lang P, Charpentier B et al.. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de l'Ile-de-France (GCIF).  Medicine (Baltimore). 2000;  79 90-102
• 59 Ruggenenti P. Post-transplant hemolytic-uremic syndrome.  Kidney Int. 2002;  62 1093-1104
• 60 Taylor C M. Complement factor H and the haemolytic uraemic syndrome.  Lancet. 2001;  358 1200-1202
• 61 Remuzzi G, Ruggenenti P, Codazzi D et al.. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.  Lancet. 2002;  359 1671-1672
• 62 Humar A, Jessurun J, Sharp H L, Gruessner R W. Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports.  Transpl Int. 1999;  12 387-390
• 63 Mercadal L, Petitclerc T, Assogba U, Beaufils H, Deray G. Hemolytic and uremic syndrome after heart transplantation.  Am J Nephrol. 2000;  20 418-420
• 64 Shitrit D, Starobin D, Aravot D et al.. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient.  Transplant Proc. 2003;  35 627-628
• 65 Fortin M C, Raymond M A, Madore F et al.. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.  Am J Transplant. 2004;  4 946-952
• 66 Murer L, Zacchello G, Bianchi D et al.. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation.  J Am Soc Nephrol. 2000;  11 1132-1137
• 67 Asaka M, Ishikawa I, Nakazawa T et al.. Hemolytic uremic syndrome associated with influenza A virus infection in an adult renal allograft recipient: case report and review of the literature.  Nephron. 2000;  84 258-266
• 68 Mor E, Lustig S, Tovar A et al.. Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection?.  Transplant Proc. 2000;  32 686-687
• 69 McLeod B C. Thrombotic microangiopathies in bone marrow and organ transplant patients.  J Clin Apheresis. 2002;  17 118-123
• 70 Kwaan H C, Gordon L I. Thrombotic microangiopathy in the cancer patient.  Acta Haematol. 2001;  106 52-56
• 71 Hahn H, Ha I S, Choi H S et al.. Acute leukemia: an association with atypical hemolytic uremic syndrome.  Pediatr Nephrol. 2003;  18 703-705
• 72 Majhail N S, Hix J K, Almahameed A. Carcinoma of the colon in a patient presenting with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Mayo Clin Proc. 2002;  77 873
• 73 Lee J L, Lee J H, Kim M K et al.. A case of bone marrow necrosis with thrombotic thrombocytopenic purpura as a manifestation of occult colon cancer.  Jpn J Clin Oncol. 2004;  34 476-480
• 74 Sugimoto T, Saigo K, Shin T et al.. Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura.  Acta Haematol. 2005;  113 198-203
• 75 Fontana S, Gerritsen H E, Kremer Hovinga J, Furlan M, Lämmle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.  Br J Haematol. 2001;  113 100-102
• 76 Lesesne J B, Rothschild N, Erickson B et al.. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.  J Clin Oncol. 1989;  7 781-789
• 77 Snyder Jr H W, Mittelman A, Oral A et al.. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma.  Cancer. 1993;  71 1882-1892
• 78 Korec S, Schein P S, Smith F P et al.. Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion.  J Clin Oncol. 1986;  4 210-215
• 79 Borghardt E J, Kirchertz E J, Marten I, Fenchel K. Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome.  Transfus Sci. 1998;  19(suppl) 5-7
• 80 Christidou F, Athanasiadou A, Kalogiannidis P et al.. Therapeutic plasma exchange in patients with grade 2-3 hematopoietic stem cell transplantation-associated thrombotic thrombocytopenic purpura: a ten-year experience.  Ther Apher Dial. 2003;  7 259-262
• 81 Bosch T, Buhmann R, Lennertz A, Samtleben W, Kolb H J. Therapeutic plasma exchange in patients suffering from thrombotic microangiopathy after allogeneic bone marrow transplantation.  Ther Apher. 1999;  3 252-256
• 82 Bueno Jr D, Sevigny J, Kaplan A A. Extracorporeal treatment of thrombotic microangiopathy: a ten year experience.  Ther Apher. 1999;  3 294-297
• 83 Llamas P, Romero R, Cabrera R, Sanjuan I, Fores R, Fernandez M N. Management of thrombotic microangiopathy following allogeneic transplantation: what is the role of plasma exchange?.  Bone Marrow Transplant. 1997;  20 305-306
• 84 Chown S R, Goulden N, Cornish J M et al.. The role of plasma exchange for TTP/HUS post-bone marrow transplant.  Bone Marrow Transplant. 1996;  17 898-899